SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-20-001197
Filing Date
2020-05-14
Accepted
2020-05-14 16:40:13
Documents
43
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm 6-K 9048
2 QUARTERLY REPORT FOR THE QUARTER ENDED MARCH31, 2020 nymox_ex991.htm EX-99.1 227866
3 CEO CERTIFICATIONS nymox_ex992.htm EX-99.2 12286
4 CFO CERTIFICATIONS nymox_ex993.htm EX-99.3 12204
11 nymox_ex991img1.jpg GRAPHIC 13453
  Complete submission text file 0001640334-20-001197.txt   1498997

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE DOCUMENT nymx-20200331.xml EX-101.INS 239384
6 XBRL TAXONOMY EXTENSION SCHEMA nymx-20200331.xsd EX-101.SCH 36398
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymx-20200331_cal.xml EX-101.CAL 24789
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymx-20200331_def.xml EX-101.DEF 51065
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymx-20200331_lab.xml EX-101.LAB 139657
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymx-20200331_pre.xml EX-101.PRE 107016
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 20878441
SIC: 2835 In Vitro & In Vivo Diagnostic Substances